Osteosarcoma Arising as a Secondary Malignancy Following Treatment for Hematologic Cancer - A Report of 33 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS)

Sep 21, 2026

Uploaded by Eliana

Purpose: Osteosarcoma may develop as a secondary malignancy after prior leukemias or lymphomas; this report aims to deepen understanding of these rare events. Patients and methods: The Cooperative Osteosarcoma Study Group database was searched for individuals whose osteosarcoma occurred after a previous hematological malignancy, documenting presentation, prior treatments, and outcomes. Key findings: Radiotherapy for the hematologic cancer emerged as a major risk factor; genetic tumor predispositions were identified in a subset. Modern interdisciplinary management appears feasible with adaptations after prior therapies, while prognosis is worse than in patients without preceding cancers.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages12

Reading Time30 min

AccessFree to download

Simple Summary

Abstract

Purpose

Patients and methods

cancers Article Osteosarcoma Arising as a Secondary Malignancy Following Treatment for Hematologic Cancer: A Report of 33 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS) Stefan S. Bielack 1,2, *, Vanessa Mettmann 1, Daniel Baumhoer 3, Claudia Blattmann 1, Birgit Burkhardt 2, Christoph K. W. Deinzer 4, Leo Kager 5,6, Matthias Kevric 1, Christine Mauz-Körholz 7,8, Peter Müller-Abt 9, Dirk Reinhardt 10, Alexandru-Anton Sabo 1, Martin Schrappe 11, Benjamin Sorg 1, Reinhard Windhager 12 and Stefanie Hecker-Nolting 1 Citation: Bielack, S.S.; Mettmann, V.; Baumhoer, D.; Blattmann, C.; Burkhardt, B.; Deinzer, C.K.W.; Kager, L.; Kevric, M.; Mauz-Körholz, C.; Müller-Abt, P.; et al. Osteosarcoma Arising as a Secondary Malignancy Following Treatment for Hematologic Cancer: A Report of 33 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS) . Cancers 2024, 16, 1836. [https://](https://)[ ](https://)[doi.org/10.3390/cancers16101836](doi.org/10.3390/cancers16101836) Academic Editor: Anthony Elias Received: 22 March 2024 Revised: 12 April 2024 Accepted: 8 May 2024 Published: 11 May 2024 Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) . 1 Klinikum Stuttgart—Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend-und Frauenmedizin, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), 70174 Stuttgart, Germany; [vanessa.mettmann@umm.de](vanessa.mettmann@umm.de) (V.M.); [c.blattmann@klinikum-stuttgart.de](c.blattmann@klinikum-stuttgart.de) (C.B.); [m.kevric@klinikum-stuttgart.de](m.kevric@klinikum-stuttgart.de) (M.K.); [a.sabo@klinikum-stuttgart.de](a.sabo@klinikum-stuttgart.de) (A.-A.S.); [b.sorg@klinikum-stuttgart.de](b.sorg@klinikum-stuttgart.de) (B.S.); [s.hecker-nolting@klinikum-stuttgart.de](s.hecker-nolting@klinikum-stuttgart.de) (S.H.-N.) 2 Klinik für Kinder-und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Münster, 48149 Münster, Germany; [birgit.burkhardt@ukmuenster.de](birgit.burkhardt@ukmuenster.de) 3 Knochentumor Referenzzentrum, Institut für Medizinische Genetik und Pathologie, Universitätsspital und Universität Basel, 4031 Basel, Switzerland; [daniel.baumhoer@usb.ch](daniel.baumhoer@usb.ch) 4 Abteilung Innere Medizin VIII—Medizinische Onkologie und Pneumologie, Universitätsklinikum Tübingen, 72076 Tübingen, Germany; christoph.deinzer@med.uni-tuebingen.de 5 St. Anna Kinderspital, Universitätsklinik für Kinder-und Jugendheilkunde der Medizinischen Universität Wien, 1090 Vienna, Austria 6 St. Anna Children’s Cancer Research Institute (CCRI), 1090 Vienna, Austria 7 Pädiatrische Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Justus-Liebig-Universität, 35390 Gießen, Germany; [christine.mauz-koerholz@paediat.med.uni-giessen.de](christine.mauz-koerholz@paediat.med.uni-giessen.de) [8](8 Medizinische Fakult)[ Medizinische Fakult](8 Medizinische Fakult)ä[t der Martin-Luther-Universit](t der Martin-Luther-Universit)ä[t Halle-Wittenberg](t Halle-Wittenberg), [06120 Halle](06120 Halle), [Germany](Germany) [9](9 Radiologisches Institut)[ Radiologisches Institut](9 Radiologisches Institut) ([Kinderradiologie](Kinderradiologie)), Zentrum für Kinder-, Jugend-und Frauenmedizin, Klinikum Stuttgart—Olgahospital, 70174 Stuttgart, Germany; [p.mueller-abt@klinikum-stuttgart.de](p.mueller-abt@klinikum-stuttgart.de) [10](10 Klinik f)[ Klinik f](10 Klinik f)ü[r Kinderheilkunde III](r Kinderheilkunde III), [Zentrum f](Zentrum f)ü[r Kinder-](r Kinder-)und Jugendmedizin, Universitätsmedizin Essen, 45147 Essen, Germany; [dirk.reinhardt@uk-essen.de](dirk.reinhardt@uk-essen.de) 11 Klinik für Kinder-und Jugendmedizin I, Campus Ki

FAQs

What is the purpose of this report on osteosarcoma after hematologic cancer?

To increase knowledge about rare secondary osteosarcoma events that arise after leukemias or lymphomas, and to document potential risk factors and outcomes.

How were the patients identified and what data were evaluated?

Individuals developing osteosarcoma after a prior hematological malignancy were identified from the Cooperative Osteosarcoma Study Group database, with details on presentation, prior treatments, and outcomes.

What treatment-related and biological factors were suggested by the findings?

Radiotherapy given to treat the hematologic cancer appeared as a major risk factor, and genetic tumor predispositions were found in a subset of patients.

Sep 21, 2026

Uploaded by Eliana